Related Experiment Videos
Insights
Maternal diabetes impacts fetal growth. Insulin is crucial for late fetal development, while glucagon plays a role after birth.
Area of Science:
- Endocrinology
- Fetal Development
- Metabolism
Background:
- The fetal endocrine pancreas produces insulin and glucagon, hormones metabolized within the fetal-placental unit.
- Maternal diabetes can disrupt fetal hormone balance and growth.
- Insulin is essential for fetal development, while glucagon's role is more prominent postnatally.
Purpose of the Study:
- To investigate the roles of insulin and glucagon in fetal development and metabolism.
- To understand the impact of maternal hyperglycemia and diabetes on fetal growth and hormone homeostasis.
Main Methods:
- Review of existing literature on fetal endocrine function and maternal diabetes.
- Analysis of hormonal regulation in the fetal-placental unit.
- Examination of the effects of altered maternal glycemia on fetal outcomes.
Main Results:
- Maternal hyperglycemia leads to fetal hyperglycemia, hyperinsulinemia, and macrosomia.
- Strict maternal glucose control prevents fetal macrosomia.
- Fetal insulin deficiency results in growth restriction after 30 weeks' gestation.
- Insulin acts as the primary anabolic hormone in late fetal life.
Conclusions:
- Insulin is the major anabolic hormone regulating late fetal growth.
- Glucagon's primary role is in newborn gluconeogenesis, not fetal growth.
- Effective maternal glycemic control is vital for preventing adverse fetal outcomes in diabetic pregnancies.
Abstract:
The developing fetal endocrine pancrease produces both insulin and glucagon from an early stage in human development. These hormones do not cross the placenta and must be metabolized within the fetal-placental unit. Altered substrate metabolism in the gestational diabetic of the insulin dependent diabetic patient can pertubate normal fetal hormone homeostasis. Maternal hyperglycemia produces fetal hyperglycemia, hyperinsulinemia, and macrosomia while meticulous regulation of maternal glycemia abolishes the fetal macrosomia. Conversely, low levels of insulin or absence of fetal insulin results in fetal growth failure after 30 weeks' gestation. These examples, plus studies of the end-organ defects (receptors) in insulin metabolism, indicate that insulin is the major anabolic hormone of late fetal life. Glucagon appears to play less of a role in fetal life but has a homeostatic function in gluconeogenesis in the newborn. No specific growth-promoting role has been demonstrated for glucagon.